Original Article

Subregion-specific $^{18}$F-FDG PET-CT radiomics for the pre-treatment prediction of EGFR mutation status in solid lung adenocarcinoma

Yun Wang$^{1*}$, Guang Yang$^{2*}$, Xinyi Gao$^3$, Linfa Li$^4$, Hongzhou Zhu$^4$, Heqing Yi$^5$

$^1$Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China; $^2$Department of Physics, Shanghai Key Laboratory of Magnetic Resonance, East China Normal University, Shanghai 200062, China; $^3$Department of Radiology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China. *Equal contributors.

Received November 17, 2023; Accepted March 7, 2024; Epub April 25, 2024; Published April 30, 2024

Abstract: This study aimed to assess the efficacy of fluor-18 fluorodeoxyglucose ($^{18}$F-FDG) PET/CT using sub-regional-based radiomics in predicting epidermal growth factor receptor (EGFR) mutation status in pretreatment patients with solid lung adenocarcinoma. A retrospective analysis included 269 patients (134 EGFR+ and 135 EGFR-) who underwent pretreatment $^{18}$F-FDG PET/CT scans and EGFR mutation testing. The most metabolically active intratumoral sub-region was identified, and radiomics features from whole tumors or sub-regional regions were used to build classification models. The dataset was split into a 7:3 ratio for training and independent testing. Feature subsets were determined by Pearson correlation and the Kruskal Wallis test and radiomics classifiers were built with support vector machines or logistic regressions. Evaluation metrics, including accuracy, area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were employed for different classifiers. Results indicated that the sub-region-based classifier outperformed the whole-tumor classifier in terms of accuracy (73.8% vs. 66.2%), AUC (0.768 vs. 0.632), specificity (65.0% vs. 50.0%), PPV (70.2% vs. 62.2%), and NPV (78.8% vs. 74.0%). The clinical classifier exhibited an accuracy of 75.0%, AUC of 0.768, sensitivity of 72.5%, specificity of 77.5%, PPV of 76.3%, and NPV of 73.8%. The combined classifier, incorporating sub-region analysis and clinical parameters, demonstrated further improvement with an accuracy of 77.5%, AUC of 0.807, sensitivity of 77.5%, specificity of 77.5%, and PPV of 77.5%. The study suggests that sub-region-based $^{18}$F-FDG PET/CT radiomics enhances EGFR mutation prediction in solid lung adenocarcinoma, providing a practical and cost-efficient alternative to invasive EGFR testing.

Keywords: Radiomics, epidermal growth factor receptor, solid lung adenocarcinoma, $^{18}$F-FDG PET/CT, prediction

Introduction

Lung cancer represents a ubiquitous and highly consequential global health challenge, characterized by the highest rates of both mortality and morbidity on a worldwide scale. Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all diagnosed lung cancer cases [1, 2]. NSCLC harboring epidermal growth factor receptor (EGFR) mutations exhibits heightened responsiveness to EGFR tyrosine kinase inhibitors (TKIs), constituting a targeted therapeutic approach. Implementation of EGFR-targeted therapy holds the promise of enhancing both median overall survival (OS) and progression-free survival (PFS) for patients within this particular subset [3]. Initial EGFR gene testing before treatment has been recommended by several clinical guidelines [4]. The prevailing clinical protocol for EGFR genotyping relies on biopsy procedures, a methodology fraught with potential technical constraints such as insufficient tissue availability, complications associated with invasive biopsy, and the inherent risk of procedural complications [5].

Genotypic heterogeneity significantly influences the diversity observed in the tumor microenvironment, encompassing aspects such as tumor metabolism, which can manifest in imaging modalities. $^{18}$F-FDG positron emission tomography (PET) relies on varying rates of $^{18}$F-FDG uptake, and in the context of lung cancer cells with EGFR mutations, the uptake of $^{18}$F-FDG may be modulated by the signaling activity of the EGFR pathway [6]. The incorporation of $^{18}$F-FDG PET/computed tomography (CT), a hybrid imaging modality that integrates $^{18}$F-FDG PET for the quantitative assessment of glucose metabolism with CT for X-ray absorption detection, is advocated for the routine staging of patients diagnosed with lung adenocarcinoma as an integral component of the initial clinical evaluation. While prior investigations employing $^{18}$F-FDG PET/CT to predict gene mutations in lung cancer have predominantly centered on visual analysis or conventional semi-quantitative parameters, such as standardized uptake values (SUVs) [7, 8], without considering CT information and various textures reflecting heterogeneity [8]. With the application of medical artificial intelligence, it has become feasible to find fast, convenient, and noninvasive surrogates for EGFR genotyping. Quantitative imaging analysis employing radiomics methodology has the capacity to extract a robust set of objective and high-throughput imaging features from provided images, facilitating automated gene prediction. Consequently, radiomics holds promise for its application in genotyping within the context of $^{18}$F-FDG PET/CT.

Previous radiomics analysis usually set the whole tumor volume as the region of interest (ROI). However, many
studies have found that information from different sub-regions of the tumor contributes differently to classification. Whole tumor analysis assumes that the tumor is homogeneous or well mixed throughout the whole volume. In addition, regional differences are apparent within the whole tumor on medical images, such as $^{18}$F-FDG PET. In recent years, efforts have been made in developing imaging analysis based on sub-regions instead of whole tumors [9, 10]. Regional disparities within the tumor may manifest distinct metabolic patterns on $^{18}$F-FDG PET, thereby suggesting that information derived from specific sub-regions could serve as valuable indicators for the assessment of tumor heterogeneity and genotype.

A study conducted by Stanford University demonstrated that the metabolically most active sub-region, as identified through FDG PET, can function as a reliable predictor of overall survival (OS) and progression outside the treatment field in patients with previously treated lung cancer [11]. Therefore, radiomics features can be used along with other clinical data to improve diagnostic accuracy.

We postulated that the EGFR genetic profile of solid lung adenocarcinomas could be discerned in their phenotypic and metabolic traits, and that these characteristics could be more effectively elucidated through radiomics analysis employing sub-regions in $^{18}$F-FDG PET/CT. Our goal was to formulate an innovative integrated radiomics classifier for predicting EGFR mutation status in patients with solid lung adenocarcinoma before treatment. This classifier incorporates both metabolic and anatomical information extracted from the most metabolically dynamic sub-region within the tumor on $^{18}$F-FDG PET/CT, alongside clinical information.

**Materials and methods**

This single-center analysis was approved by institutional ethic committee (IRB-2020-207) and individual written informed consent for this retrospective analysis was waived.

**Patient selection**

The workflow of this study is displayed in Figure 1. We retrospectively reviewed patients with histologically proven lung adenocarcinoma who underwent pretherapy $^{18}$F-FDG PET/CT scan between December 2016 and December 2020 in Zhejiang cancer hospital. The inclusion criteria were (1) pathologically confirmed adenocarcinoma according to the latest guidelines [12]; (2) presence of solid lung lesion on pretreatment $^{18}$F-FDG PET/CT; (3) EGFR mutation tested by real-time fluorescence polymerase chain reaction (PCR); (4) < 1 months between $^{18}$F-FDG PET/CT scan and gene alteration detection; (5) no anti-tumor treatment received before PET/CT examination; and (6) no history of other malignant tumors. The exclusion criteria were (1) patients with rare EGFR mutations in exons other than between exons 18-21; (2) pure ground-glass nodule without $^{18}$F-FDG uptake and subsolid pulmonary nodule; (3) patients with chest active infections such as pneumonia that could confound $^{18}$F-FDG analysis.

**EGFR mutation testing**

In patients with stages 1-3 (n=102, 37.9%), EGFR mutation analysis was performed on histological specimens obtained through surgical resection using real-time fluo-
PET/CT radiomics for EGFR mutation


rescence PCR with the EGFR Mutations Detection Kit (Human EGFR gene mutation detection kit, AmoyDx, Xiamen, Fujian, China), and the outcome was interpreted following the manufacturer’s instructions. For patients in stage 4 (n=167, 62.1%), the specimens submitted for EGFR mutational analysis were predominantly acquired through CT-guided core-needle biopsy (n=125, 74.9%); the remaining specimens were acquired through ultrasound-guided percutaneous biopsy (n=42, 25.1%). If any mutation in EGFR exon 18-21 was detected, the subject was considered to be an EGFR mutant. Otherwise, the tumor was considered as EGFR wild type.

Image acquisition

The imaging acquisition protocol was established following the Image Biomarker Standardization Initiative (IBSI) reporting guidelines [13]. ¹⁸F-FDG PET/CT imaging was conducted utilizing the Discovery 710 PET/CT system (GE Medical Systems, Milwaukee, Wisconsin, USA). Patients were instructed to fast for at least 6 h before the PET scan. Blood glucose level was measured to ensure that it was < 200 mg/dL. ¹⁸F-FDG was administered intravenously at a dosage of 3.7 MBq/kg. ¹⁸F-FDG PET/CT scan was performed within 1 month before treatment. In short, ¹⁸F-FDG PET/CT images were acquired 60 ± 5 min after ¹⁸F-FDG injection in accordance with the European Association of Nuclear Medicine guidelines, version 2.0 [14]. Attenuation correction CT was conducted with the following parameters: 120 kV, 150 mA, slice thickness: 3 mm. Subsequently, the PET scan was promptly acquired from the head to the upper leg, with a duration of 3 minutes per bed position. Typically, 6-8 bed positions were surveyed, adjusting as per the patient’s height. The PET images were reconstructed employing the ordered set expectation maximization algorithm. The attenuation correction of PET images was carried out with CT data, and the corrected PET images were fused with CT images. The PET parameters computed in 3D mode using vendor-provided software included: metabolic tumor volume (MTV), maximum SUV (SUV\text{\textsubscript{max}}), total lesion glycolysis (TLG), and mean SUV (SUV\text{\textsubscript{mean}}). The MTV for each solid lung adenocarcinoma lesion was assessed utilizing the adaptive threshold method. This involved selecting a volume of interest (VOI) on the axial image, and the size of the VOI was verified using corresponding coronal and sagittal images to encompass the entire lesion. The TLG was computed by multiplying the SUV\text{\textsubscript{mean}} by the MTV.

ROI segmentation and sub-region clustering

All lesions on CT were initially and manually contoured slice by slice by 2 radiologists (reader 1: YW with 12 years of experience; reader 2: XYG with 10 years of experience) using ITKSNAP (http://www.itksnap.org) and then scrutinized by a radiology specialist (HZZ, with 27 years of experience). Based on the method of Wu et al. [15], we further tested intra- and inter-observer reproducibility. Therefore, an intra-class correlation coefficient > 0.75 was considered to indicate satisfactory reproducibility. In this study, the segmentation of sub-regional Regions of Interest (ROIs) is performed using Otsu’s thresholding method, which divides an image into two classes, foreground and background, based on the grayscale intensity values of its pixels. This segmentation technique is implemented through the utilization of the open-source Python package, scikit-image, to automatically delineate sub-regional ROIs. The process involves leveraging Otsu’s thresholding method to efficiently separate image components, and this implementation is facilitated using the scikit-image library for enhanced precision and automation (https://scikit-image.org/docs/dev/api/skimage.filters.html#skimage.filters.threshold_otsu). Figure 2 illustrates an example of whole-tumor ROI and sub-region ROI.

Feature extraction, selection and model construction

We applied normalization to the feature matrix. Radiomic features were extracted from each whole-tumor ROI and
sub-region ROI with Pyradiomics (http://pyradiomics.readthedocs.io/en/latest/index.html). Shape features, together with grayscale and texture features from the original image, wavelet transform, and LoG hyper-parameters (lambda =1.0, 3.0, 5.0) filtered images were extracted.

Texture features encompassed various types, including Gray Level Co-occurrence Matrix (GLCM), Gray Level Size Zone Matrix (GLSZM), Gray Level Run Length Matrix (GLRLM), Neighboring Gray Tone Difference Matrix (NGTDM), and Gray Level Dependence Matrix (GLDM). The primary objectives encompass addressing imbalances in the training dataset via the Synthetic Minority Oversampling Technique (SMOTE) and each feature vector underwent a normalization process by subtracting its mean value and dividing by the module of the vector. Given the discrepancy between the relatively small sample size and the high-dimensional feature size, dimension reduction and feature selection were executed. For each feature exhibiting a Pearson correlation coefficient (PCC) value of > 0.99, one of them was randomly omitted, resulting in a reduction of the feature space dimension and mitigating feature redundancy.

Before model construction, measures were taken to eliminate highly correlated features, reduce dimensionality through feature selection using Kruskal Wallis, and utilize logistic regression as the classifier. The F-value was calculated to evaluate the relationship between features and the label. Features were classified depending on the corresponding F-value and top N features were determined through cross-validation with 5-fold on the training dataset based on the model's performance on the validation dataset. Classifier 1 was built based on features extracted from the whole-tumor ROIs. Classifier 2 was built based on features extracted from the sub-regional ROIs. Classifier 3 was a clinical model (gender, age, TNM stage, smoking history, MTV, TLG, and SUV<sub>max</sub>). Classifier 2 and 3 prediction probabilities were combined for building model 4. We used a support vector machine (SVM) with a linear kernel - an effective and robust classifier that searches the hyperplane to separate the cases with different labels - to build classifier 1 and 2. We used the linear kernel for its simplicity and interpretability. For classifier 3 and 4, we adopted logistic regression, which is a linear classifier that combines all features. To determine the number of retained features in each model, a 5-fold cross-validation was performed on training dataset, and the final features number was set according to cross-validation results.

**Prognostic performance evaluation**

The area under receiver operation characteristic (ROC) curve (AUC) value were computed to evaluate and compare the prediction performance. Meanwhile, other quantitative evaluation indices involving accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were also computed to evaluate the prediction performance. In addition, we estimated the 95% confidence interval by bootstrapping with 1000 samples. All the above processes were implemented with FeAture Explorer (FAE, V 0.3.6) on Python (3.7.6) [16].

**Results**

**Patient characteristics**

Based on the provided criteria, a total of 269 patients diagnosed with lung adenocarcinoma were enrolled in this study. The cohort comprised 155 males and 114 females, with an average age of 63.0 ± 11.0 years (range from 29 to 89). Among the participants, 134 cases exhibited EGFR mutation, constituting 49.8% of the total, while 135 cases were classified as EGFR wild type, representing the remaining 50.2%. The proportion of female patients with EGFR mutations is higher than that of males (56.0% vs. 44.0%). Additionally, EGFR wild-type patients exhibit a higher prevalence of smoking history compared to EGFR mutant patients (62.2% vs. 33.6%). EGFR wild-type patients demonstrate significantly elevated SUV<sub>max</sub>, MTV, and TLG compared to EGFR mutant patients, with all differences reaching statistical significance (all P < 0.05). There were no statistically significant differences in age and TNM staging between EGFR mutant and wild-type groups (both P > 0.05), as shown in Table 1. Representative 18F-FDG PET/CT images of patients with EGFR mutations and wild-type are illustrated in Figure 3. The clinical characteristics of the patients are summarized in Table 1.

**Feature selection, model establishment and evaluation**

269 patients were randomly split into the training set (EGFR mutant: 94; EGFR wild type: 95; total: 189) and the testing set (EGFR mutant: 40; EGFR wild type: 40; total: 80).

**Classifier 1: SVM training and testing based on whole-tumor ROI:** In the SVM training and testing phase, exclusive attention was directed towards features originating from whole-tumor ROIs. Through meticulous scrutiny, the classifier discerned the top 12 features from a comprehensive pool of 1130, culminating in the development of an SVM classifier exhibiting a diagnostic accuracy of 66.2% in the test cohort. The AUC was computed as 0.733 in the training cohort. The comprehensive performance metrics of the whole-tumor classifier included an accuracy of 66.2%, AUC of 0.632 (95% CI: 0.507-0.763), sensitivity at 82.5%, specificity at 50.0%, PPV at 62.2%, and NPV at 74.0%. The acquisition of diagnostic proficiency for EGFR mutation status through the SVM classifier based on Whole-Tumor ROIs is underscored by these results, elucidating its capability to effectively categorize instances within the evaluated datasets. The ROC curve for classifier 1 is visually depicted in Figure 4A.

**Classifier 2: SVM training and testing based on sub-region ROI:** In this phase of the study, SVM classifier training and testing were exclusively conducted utilizing features...
The clinical model was trained using clinical variables (gender, age, smoking history, and TNM stage) along with PET parameters. ROC curve analysis was employed to assess the predictive efficacy of the clinical model in diagnosing EGFR mutations. This model exhibited an AUC of 0.753, accuracy of 66.7% in the training cohort. In the independent test cohort, the clinical classifier demonstrated metrics with values of 75.0% accuracy, AUC of 0.768 (95% CI: 0.658-0.868), sensitivity at 72.5%, specificity at 77.5%, PPV at 76.3%, and NPV at 73.8%. The ROC curve of classifier 3 is visually depicted in Figure 4C, providing a graphical representation of the classifier’s discriminative performance.

**Classifier 4: combined model:** In this methodology, the prediction probabilities generated by classifier 2 and 3 were utilized to train a combined model. Following the preprocessing and feature selection steps in the development of the classification model, feature parameters for the clinical model were determined. The clinical model was trained using clinical variables (gender, age, smoking history, and TNM stage) along with PET parameters. ROC curve analysis was employed to assess the predictive efficacy of the clinical model in diagnosing EGFR mutations. This model exhibited an AUC of 0.753, accuracy of 66.7% in the training cohort. In the independent test cohort, the clinical classifier demonstrated metrics with values of 75.0% accuracy, AUC of 0.768 (95% CI: 0.658-0.868), sensitivity at 72.5%, specificity at 77.5%, PPV at 76.3%, and NPV at 73.8%. The ROC curve of classifier 3 is visually depicted in Figure 4C, providing a graphical representation of the classifier’s discriminative performance.
PET/CT radiomics for EGFR mutation

The performance metrics in the independent test cohort were as follows: an accuracy of 77.5%, an AUC of 0.807 (95% CI: 0.699-0.896), and both sensitivity and specificity at 77.5%. Additionally, the positive predictive value (PPV) and negative predictive value (NPV) were both registered at 77.5%.

![Figure 4](image-url)

Figure 4. ROC curves for four distinct models predicting EGFR mutations. ROC curve for classifier 1 using whole-tumor ROI (A). ROC curve for classifier 2 using sub-regional ROI (B). ROC curve for classifier 3 based on the clinical model (C). ROC curve for classifier 4 representing the combined model (D).

### Table 2. Comparison of the model performance in terms of different evaluation

<table>
<thead>
<tr>
<th>Models</th>
<th>Accuracy</th>
<th>AUC</th>
<th>95% CI</th>
<th>NPV</th>
<th>PPV</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classifier 1</td>
<td>0.662</td>
<td>0.632</td>
<td>0.507-0.763</td>
<td>0.740</td>
<td>0.622</td>
<td>0.825</td>
<td>0.500</td>
</tr>
<tr>
<td>Classifier 2</td>
<td>0.738</td>
<td>0.768</td>
<td>0.657-0.871</td>
<td>0.788</td>
<td>0.702</td>
<td>0.825</td>
<td>0.650</td>
</tr>
<tr>
<td>Classifier 3</td>
<td>0.750</td>
<td>0.768</td>
<td>0.658-0.868</td>
<td>0.738</td>
<td>0.763</td>
<td>0.725</td>
<td>0.775</td>
</tr>
<tr>
<td>Classifier 4</td>
<td>0.775</td>
<td>0.807</td>
<td>0.699-0.896</td>
<td>0.775</td>
<td>0.775</td>
<td>0.775</td>
<td>0.775</td>
</tr>
</tbody>
</table>

AUC, area under curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; Classifier 1, whole-tumor ROI based model; Classifier 2, sub-regional ROI based model; Classifier 3, clinical model; Classifier 4, combined model.

...
Discussion

In the standard care protocol for pretreatment of NSCLC patients, determining EGFR mutation status plays a crucial role in the selection of individuals who may potentially benefit from EGFR TKI treatment and predicting subsequent clinical outcomes [12]. However, the current clinical standard for EGFR genotyping, reliant on biopsy procedures, is invasive and prone to certain limitations. These limitations include patient reluctance, challenges related to the location or size, potential sampling errors, procedural complexities, extended testing durations, limited samples availability, compromised patient health, and spatial and temporal heterogeneity within the tumor [17, 18]. Alternative strategies such as radiogenetic analysis, may help overcome these limitations.

In this retrospective study, we investigated the feasibility of radiogenomic analysis to predict EGFR genotyping in 269 pretreated patients suffering solid lung adenocarcinoma. The sub-region-based machine learning classifier (classifier 2) outperformed the traditional whole-tumor-based machine learning classifier (classifier 1) with a higher AUC in the independent test group. Integration of the predictive probabilities from clinical features and sub-region Region of Interest (ROI) features, the combined radiogenomics model (classifier 4) demonstrated robust diagnostic performance. By incorporating radiomics metabolic features from 18F-FDG PET, radiomics structural features from CT, relevant clinical factors, and sub-region-based radiomics, this study comprehensively explored the hybrid 18F-FDG PET/CT image information to an unprecedented extent. Hence, the combined sub-region-based pretherapy hybrid 18F-FDG PET/CT machine learning radiogenomics classifier could accurately predict EGFR mutation in solid lung adenocarcinoma, potentially serving as a noninvasive surrogate for traditional EGFR status test. It should be noted that the majority of EGFR mutations occur in hotspots between exons 18 and 20 [2]. However, targeted therapies are approved for patients with “classical” mutations and a small number of other mutations. Furthermore, effective therapies have not been identified for additional EGFR mutations [19]. Therefore, rare EGFR mutations were not included in this study.

In contradistinction to the general population of NSCLC patients, those harboring EGFR kinase domain mutations are more predisposed to being of Asian ethnicity, female gender, exhibiting adenocarcinoma histology, and having no history of smoking [4, 6]. Our study similarly identifies a lack of smoking history and female gender as predictors of EGFR mutation status. Notably, no statistically significant differences in terms of age and tumor stage were observed among distinct EGFR mutation groups (all P > 0.05).

18F-FDG uptake on PET may be a noninvasive biomarker of underlying tumor genotypes. The EGFR gene mutation enhances glucose metabolism through the Akt signaling cascade in neoplastic cells, thereby inducing their proliferation and enhancing viability [20]. Subjective characteristics analysis depending on the naked eye or conventional 18F-FDG PET parameters were most commonly used to predict EGFR mutation status in previous EGFR genotyping-related 18F-FDG PET/CT researchers. Those studies have investigated the relationship between SUVmax and SUVpeak measured from PET and led to contradictory results [6, 21]. Kim et al. found that all the metabolic and volumetric 18F-FDG PET/CT values were significantly lower in EGFR mutant than EGFR wild type lung adenocarcinomas [22]. In current study, EGFR mutant subset showed lower SUVmax than EGFR wild subset. Various studies have identified specific SUVmax cutoff values indicative of EGFR mutation in NSCLC patients [6, 23-27]. Lv et al. [6] reported SUV max < 7.0 as a predictor (AUC=0.557, n=849), Na et al. [28] SUVmax < 9.2 predictive (AUC=0.74, n=100), Mak et al. [29] observed SUVmax < 5.0 as a predictor (AUC=0.62, n=100), Cho et al. [30] identified SUVmax < 9.6 as predictive (AUC=0.68, n=61), and Guan et al. [31] determined SUVmax < 8.1 as predictive (AUC=0.65, n=316). Conversely, Ko et al. [31] established SUVmax ≥ 6 (AUC=0.63, n=132) as predictive in lung adenocarcinoma, while Huang et al. [32] found SUVmax ≥ 9.5 predictive (n=77).

However, those previous studies showed comparable inconsistency and relatively low discriminative abilities, because traditional PET parameters including SUVmax and SUVpeak do not include any spatial or texture information, which greatly reflecting EGFR mutation biology and tumor heterogeneity [33]. In the capacity of a hybrid imaging methodology, our 18F-FDG PET/CT radiogenomic analysis derived radiomics characteristics from both CT and 18F-FDG PET, thereby extensively harnessing imaging details through machine learning techniques. Currently, some radiogenomics studies on NSCLC EGFR mutation status have involved 18F-FDG PET. Yip et al. [21] developed a 21 features-based radiomics model could distinguish the differences of tumor metabolic phenotypes caused by EGFR mutation and might potentially serve as noninvasive imaging biomarkers for somatic mutations. Rios et al. [27] analyzed the radiomic characteristics of 763 patients with lung adenocarcinoma from 4 medical centers and found that 16 features correlate with EGFR mutations. Li et al. [34] built a 18F-FDG PET/CT-based radiogenomics signature for EGFR mutation classification reaching an AUC of 0.805, an accuracy of 80.798%, a sensitivity of 0.826, and a specificity of 0.783.

Failure to consider sub-region variations may reduce the diagnostic power of useful imaging biomarkers. By leveraging the most metabolically active sub-regional information of 18F-FDG PET/CT, we proved the sub-region-based machine learning classifier outperformed traditional whole-tumor-based machine learning classifier, which is consistent with previous sub-regional radiomics analyses [11, 35]. After assessing copy number alterations, Xie et al. [9] further found that the sub-region-based CT
Radiomics model have the potential to reflect esophageal tumor gene mutation. Furthermore, Xia et al. [35] constructed an eight sub-regional radiomics feature set for hepatocellular carcinoma, derived from enhanced CT values, and local entropy. These features were found to be significantly correlated with prognostic gene modules, with two of them specifically associated with overall survival (OS). However, the previous sub-region-based radiomics approaches extracted features from CT images only. Önner et al. [36] found that tumoral heterogeneity (TH) measurement with histogram-based textural features (HTFs) may contribute to conventional metabolic parameters in guiding precision medicine for invasive lung adenocarcinoma (ILA). In present study, a brighter sub-region on 18F-FDG PET indicating higher 18F-FDG uptake was automatically segmented into sub-region ROIs using Otsu thresholding method, which applied to both 18F-FDG PET and CT images for texture features extraction, involving not only underlying structural but also metabolic characteristics. Moreover, many previous researches proved the clinical factors potentially associated with EGFR mutation status [37]. Zhang et al. [38] found that combining radiomics features with clinical risk factors can yield added predictive value for EGFR mutation classification in NSCLC. In the present study, we integrated the prediction probability of clinical features and sub-region ROI features; the fused model showed a significantly better ability distinguishing EGFR mutants from the wild type, supporting the complementarity between clinical and radiomics features. Chang et al. [39] analyzed 583 cases of lung adenocarcinoma patients using 18F-FDG PET/CT images. They found that the PET/CT radiomics-clinical combined model (AUC=0.84) outperformed the PET/CT radiomics model (AUC=0.76) and the clinical model (AUC=0.81) in predicting EGFR mutations. Wang et al. [40] analyzed CT images and EGFR gene sequencing data from 18,232 lung cancer patients across nine cohorts in China and the United States. In six retrospective and prospective testing cohorts, leveraging information extracted from CT images for the entire lung, a fully automated artificial intelligence system (FAIS) exhibited an AUC range of 0.748-0.813, surpassing commonly used tumor-based deep learning models. The FAIS, when combined with clinical factors (FAIS-C model), demonstrated a significant correlation between predicted genotypes and the prognosis of EGFR-TKI treatment. In this study, the combined classifier, which integrates sub-region analysis and clinical parameters, demonstrated improved predictive efficacy in determining EGFR mutation status compared to other classifiers. In comparison to previously reported research methodologies, although our results did not demonstrate a predictive efficacy surpassing other study protocols, it remains worthwhile to further validate this research approach, potentially utilizing larger sample sizes or even adopting a multicenter design.

There were several limitations to this study. First, this is a single-center study with limited sample size, which may introduce bias, compromise model's generalization ability, as well as affect its accuracy. Hence, it is necessary to formulate a prospective multi-center study with a larger population to validate this model. Second, the EGFR mutation status of only one tissue type (lung adenocarcinoma) was analyzed. Therefore, the predictive efficacy of this model in other lung cancer types necessitates further investigation.

**Conclusion**

This study substantiated that the integrated sub-region-based pretherapy 18F-FDG PET/CT machine learning radiogenomics exhibited commendable predictive efficacy in discerning EGFR mutation status during the pretreatment phase of solid lung adenocarcinoma. This could potentially serve as a reasonably accurate, convenient, and noninvasive alternative to invasive biopsy for identifying suitable candidates for EGFR TKI therapy.

**Acknowledgements**

This study is supported by Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission (2021KY563/2023KY068/2022PY043), and Zhejiang Province Natural Science Foundation of China (Grant number: LTGY24H180013).

**Disclosure of conflict of interest**

None.

**Address correspondence to:** Dr. Heqing Yi, Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China. Tel: +86-571-88122332; Fax: +86-571-88122332; E-mail: yihq@zjcc.org.cn; yheqing1989@163.com; Dr. Hongzhou Zhu, Department of Radiology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China. Tel: +86-571-88122222; Fax: +86-571-88122222; E-mail: zhuzh@zjcc.org.cn

**References**


PET/CT radiomics for EGFR mutation

143


